Lecanemab was found to slow cognitive decline caused by the brain-wasting disease (Stock image)
(Picture: PA Archive)A dementia charity has hailed a “historic moment” in Alzheimer’s research after a new drug was found to reduce cognitive decline in patients with early-stage disease.
Lecanemab was found to slow cognitive decline caused by the brain-wasting disease by 27 per cent over an 18-month period compared with a placebo.
The phase three clinical trial results, published by pharmaceutical firm Eisai on Wednesday, found that the drug slowed decline in participants’ memory and thinking.
It works by removing deposits of the protein amyloid which clump together in the brain at an early stage of the disease.
Scientists involved in the study said the results proved the so-called amyloid hypothesis that removing sticky deposits of the protein from the brain can stem the advance of Alzheimer’s.
Findings were evident as early as six months after participants started taking the drug.
The results represent a breakthrough for scientists after decades of failed attempts at finding an effective treatment for the disease, which affects some 55 million people globally. This figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International has warned.
Commenting on the findings, Dr Susan Kohlhaas, director of research at Alzheimer’s Research UK, said: “These top-line results, announced by the pharmaceutical company that make the drug, Eisai, offer new hope to people affected by this cruel and devastating disease.”
Prof Bart De Strooper, Director of the UK Dementia Research Institute, said: “This is hugely positive news for the millions of people affected by Alzheimer’s disease worldwide. It is a devastating condition, impacting many aspects of daily life including the ability to form memories, problem-solve and look after ourselves. Effective treatments are therefore desperately needed.”
Dr Liz Coulthard, associate professor in dementia neurology at the University of Bristol, added: “This is a gold standard study in people with fairly early signs of Alzheimer’s disease.
“Although not curative, lecanemab slowed decline in day-to-day function compared to placebo. So lecanemab potentially offers prolonged good quality life in people with early signs of Alzheimer’s disease.”
The trial, which involved 1,795 participants was run by Eisai in partnership with US biotech firm Biogen.
More detail on the study will be presented to the Clinical Trials On Alzheimer’s Congress in November.
